Recent Updates
Recently added Catalysts
COLL

Collegium to Present at Jefferies and William Blair Conferences

Key Takeaway: CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference, New York, June 7th at 10 a.m. ET William Blair Annual Growt

Full Press Release Details

CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:
Jefferies Healthcare Conference, New York, June 7th at 10 a.m. ET
William Blair Annual Growth Stock Conference, Chicago, June 16th at 10 a.m. CT
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Xtampza™ ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
For Important Safety Information Visit, http://www.xtampzaer.com/

Contact Data

Vice President, Corporate Development

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: Jun 2, 2016